Allogene Therapeutics (ALLO) Cash & Equivalents (2018 - 2026)

Allogene Therapeutics has disclosed Cash & Equivalents across 9 years of filings, most recently posting $30.3 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $30.3 million, down 20.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $30.3 million (down 20.52% YoY), and the FY2025 annual result was $51.7 million, down 31.28% from the prior year.
• Cash & Equivalents came in at $30.3 million for Q1 2026 at Allogene Therapeutics, down from $51.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $161.5 million in Q2 2024 to a low of $11.8 million in Q4 2022.
• The 5-year median for Cash & Equivalents is $69.2 million (2023), against an average of $71.8 million.
• Across the five-year window, Cash & Equivalents sank 89.85% in 2022 and soared 607.1% in 2023, its largest moves.
• Allogene Therapeutics' Cash & Equivalents stood at $11.8 million in 2022, then jumped by 607.1% to $83.2 million in 2023, then fell by 9.54% to $75.2 million in 2024, then tumbled by 31.28% to $51.7 million in 2025, then plunged by 41.36% to $30.3 million in 2026.
• The last three Cash & Equivalents figures came in at $30.3 million (Q1 2026), $51.7 million (Q4 2025), and $31.6 million (Q3 2025), per Business Quant data.